JP Morgan Cazenove Keeps Its Neutral Rating on Circassia Pharmaceuticals (LON:CIR) Shares Today

April 25, 2018 - By Darrin Black

Circassia Pharmaceuticals Plc (LON:CIR) Logo

Investors sentiment increased to 1.02 in Q4 2017. Its up 0.02, from 1 in 2017Q3. It increased, as 7 investors sold Circassia Pharmaceuticals Plc shares while 37 reduced holdings. 12 funds opened positions while 33 raised stakes. 16.91 million shares or 4.21% more from 16.23 million shares in 2017Q3 were reported.

South Dakota Council owns 9,400 shares for 0.01% of their portfolio. Mason Street Limited reported 0% stake. New York-based Alliancebernstein Ltd Partnership has invested 0% in Circassia Pharmaceuticals Plc (LON:CIR). Commercial Bank Of New York Mellon Corporation reported 0% of its portfolio in Circassia Pharmaceuticals Plc (LON:CIR). Manufacturers Life Insurance Co The holds 0% of its portfolio in Circassia Pharmaceuticals Plc (LON:CIR) for 12,631 shares. Legal And General Gp Public Limited Com invested in 0% or 31,119 shares. State Bank Of Montreal Can has invested 0% in Circassia Pharmaceuticals Plc (LON:CIR). Vanguard Grp Incorporated has invested 0% in Circassia Pharmaceuticals Plc (LON:CIR). Cim Investment Mangement accumulated 7,432 shares. Rhumbline Advisers accumulated 40,442 shares or 0% of the stock. Boothbay Fund Management Limited Liability Com, New York-based fund reported 5,343 shares. Pnc Fincl Ser Gp holds 321 shares or 0% of its portfolio. Moreover, Citadel Advisors Limited Company has 0% invested in Circassia Pharmaceuticals Plc (LON:CIR) for 62,348 shares. Wilen Invest Management stated it has 0.31% of its portfolio in Circassia Pharmaceuticals Plc (LON:CIR). Texas Permanent School Fund, a Texas-based fund reported 11,154 shares.

Circassia Pharmaceuticals (LON:CIR) Rating Reaffirmed

Circassia Pharmaceuticals (LON:CIR) has had their stock rating kept as a solid Neutral by research professionals at JP Morgan Cazenove. This was revealed to clients and investors in analysts note on 24 April.

Investors sentiment increased to 1.02 in Q4 2017. Its up 0.02, from 1 in 2017Q3. It increased, as 7 investors sold Circassia Pharmaceuticals Plc shares while 37 reduced holdings. 12 funds opened positions while 33 raised stakes. 16.91 million shares or 4.21% more from 16.23 million shares in 2017Q3 were reported.

South Dakota Council owns 9,400 shares for 0.01% of their portfolio. Mason Street Limited reported 0% stake. New York-based Alliancebernstein Ltd Partnership has invested 0% in Circassia Pharmaceuticals Plc (LON:CIR). Commercial Bank Of New York Mellon Corporation reported 0% of its portfolio in Circassia Pharmaceuticals Plc (LON:CIR). Manufacturers Life Insurance Co The holds 0% of its portfolio in Circassia Pharmaceuticals Plc (LON:CIR) for 12,631 shares. Legal And General Gp Public Limited Com invested in 0% or 31,119 shares. State Bank Of Montreal Can has invested 0% in Circassia Pharmaceuticals Plc (LON:CIR). Vanguard Grp Incorporated has invested 0% in Circassia Pharmaceuticals Plc (LON:CIR). Cim Investment Mangement accumulated 7,432 shares. Rhumbline Advisers accumulated 40,442 shares or 0% of the stock. Boothbay Fund Management Limited Liability Com, New York-based fund reported 5,343 shares. Pnc Fincl Ser Gp holds 321 shares or 0% of its portfolio. Moreover, Citadel Advisors Limited Company has 0% invested in Circassia Pharmaceuticals Plc (LON:CIR) for 62,348 shares. Wilen Invest Management stated it has 0.31% of its portfolio in Circassia Pharmaceuticals Plc (LON:CIR). Texas Permanent School Fund, a Texas-based fund reported 11,154 shares.

Circassia Pharmaceuticals Plc (LON:CIR) Ratings Coverage

Among 2 analysts covering Circassia Pharmaceuticals Plc (LON:CIR), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Circassia Pharmaceuticals Plc has GBX 180 highest and GBX 130 lowest target. GBX 135’s average target is 53.06% above currents GBX 88.2 stock price. Circassia Pharmaceuticals Plc had 8 analyst reports since October 31, 2017 according to SRatingsIntel. Numis Securities maintained Circassia Pharmaceuticals Plc (LON:CIR) rating on Tuesday, April 24. Numis Securities has “Buy” rating and GBX 140 target. The stock of Circassia Pharmaceuticals Plc (LON:CIR) has “Hold” rating given on Wednesday, April 4 by Peel Hunt. The stock of Circassia Pharmaceuticals Plc (LON:CIR) earned “Hold” rating by Peel Hunt on Tuesday, April 24. The firm has “Hold” rating by Peel Hunt given on Thursday, January 4. The firm earned “Hold” rating on Thursday, March 1 by Peel Hunt. Peel Hunt maintained Circassia Pharmaceuticals Plc (LON:CIR) rating on Thursday, February 1. Peel Hunt has “Hold” rating and GBX 130 target. The firm has “Buy” rating by Numis Securities given on Monday, December 4. The company was maintained on Tuesday, October 31 by Peel Hunt.

The stock decreased 3.08% or GBX 2.8 during the last trading session, reaching GBX 88.2. About 129,097 shares traded or 25.39% up from the average. Circassia Pharmaceuticals Plc (LON:CIR) has 0.00% since April 26, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts await Circassia Pharmaceuticals Plc (LON:CIR) to report earnings on April, 27. They expect $0.32 EPS, 0.00 % or $0.00 from last year’s $0.32 per share. CIR’s profit will be $1.07M for 68.91 P/E if the $0.32 EPS becomes a reality. After $0.57 actual EPS reported by Circassia Pharmaceuticals Plc for the previous quarter, Wall Street now forecasts -43.86 % negative EPS growth.

Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease . The company has market cap of 294.12 million GBP. It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally. It currently has negative earnings. The company's asthma products comprise Fliveo that targets substitution of Flixotide, which has approved in the United Kingdom, as well as developing Seriveo that targets direct substitution of Seretide.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: